Hantz Financial Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Hantz Financial Services's NBIX Position: Q3 2026 in Review
Hantz Financial Services increased its Neurocrine Biosciences (NBIX) stake by 0.66% in Q3 2026, buying an estimated $7.07K and bringing the position to 6,750 shares worth $957K. The position accounts for 0.01% of the portfolio, ranked #530.
Hantz Financial Services first reported a position in NBIX in Q3 2020 and has held it in 25 quarters since. The position peaked at $16.6M in Q3 2022. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Hantz Financial Services held 6,750 shares of Neurocrine Biosciences worth $957K as of Q3 2026.
- Hantz Financial Services bought 44 Neurocrine Biosciences shares in Q3 2026, an estimated $7.07K.
- Neurocrine Biosciences made up 0.01% of Hantz Financial Services's portfolio in Q3 2026, its #530 holding.
- Hantz Financial Services first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 25 quarters since.
- Hantz Financial Services's Neurocrine Biosciences position peaked at $16.6M in Q3 2022.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Hantz Financial Services's 13F filing for Q3 2026, filed 9 Nov 2026.